Daily Management Review

Clinical Trials Ongoing In UK On Post-Exposure Antibody Protection


Clinical Trials Ongoing In UK On Post-Exposure Antibody Protection
Ten people in the United Kingdom have been administered antibodies in the form of emergency protection after they were exposed to the novel coronavirus, in a first of its kind protection treatment against Cvoid-19 infections.
This unique experimental jab is being offered to people who have been in close contact with a confirmed Covid-19 individual within the past eight days.
This this line of protection turns out to be effective, it can help in protecting vulnerable people who have not been given or cannot be given aCvoid-19 vaccine.
This can therefore immensely help in preventing fresh outbreaks of the disease.  
This aim of this trial, which is being carried out at the University College London Hospitals (UCLH) NHS Trust, is to see when a job comprising of two different antibodies be effective to prevent development of Covid-19, or from becoming very ill, in people who have been exposed to the disease.
For anyone who has already been exposed to the virus and the virus is in their bodies, it will be too late for giving a vaccine since it takes weeks for a vaccine to offer full protection from the disease.
On the other hand, the virus present in the body should be neutralised immediately by this monoclonal antibody treatment which has been developed by the drug maker AstraZeneca.
This new jab also ensures protection form the disease for up to a year.
This new form of protection from Covid-19 could be useful for healthcare workers, hospital patients and care home residents in the event of them being exposed to any known case of Covid-19. People with health vulnerabilities can be administered this protection by their GPS.
This unique form of protection can also help to avoid an outbreak taking place from just one or two cases such as in a student accommodation setting.
About 1,000 volunteers are intended to be recuerited by the team which is led by UCLH virologist Dr Catherine Houlihan. The team is looking to recruit volunteers from those areas where people are likely to have been exposed to the Covid-19 virus such as in hospital or a student accommodation setting.
Those who want to participate in the trials will however have to show that one of their close contacts have tested positive for Covid-19.
“The jab works by "donating" antibodies. It skips out that stage of your body doing the work" to make them,” Dr Houlihan said.
"We know that this antibody combination can neutralise the virus, so we hope to find that giving this treatment via injection can lead to immediate protection against the development of Covid-19 in people who have been exposed - when it would be too late to offer a vaccine."
This technique for protection has already been applied for post-exposure cases in the case of other viruses such as rabies, and chickenpox in pregnant people.
Another clinical trial is currently undergoing at the UCLH in which doctors and researchers are trying to find out whether this same antibody based treatment could be put to use and applied for individuals prior to them being exposed to the virus so that they may bever contract the disease at all.